BBNX Beta Bionics, Inc.

Nasdaq www.betabionics.com


$ 20.42 $ -0.61 (-2.96 %)    

Friday, 17-Oct-2025 16:55:14 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 20.02
$ 20.32
$ 19.50 x 10
$ 21.25 x 1,000
$ 19.89 - $ 20.85
$ 8.89 - $ 26.66
450,021
na
868.68M
$ 1.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-29-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-25-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Goldman Sachs analyst David Roman upgrades Beta Bionics (NASDAQ:BBNX) from Neutral to Buy and raises the price target from $...

Core News & Articles

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from ...

Core News & Articles

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from ...

Core News & Articles

Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $15 to $17.

Core News & Articles

Beta Bionics (NASDAQ:BBNX) raises FY2025 sales outlook from $82.00 million-$87.00 million to $88.00 million-$93.00 million vs $...

Core News & Articles

Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.47) ...

 sonnet-biotherapeutics-drops-5-intraday-rebounds-14-after-hours-amid-delisting-concerns

Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after...

Core News & Articles

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention t...

Core News & Articles

Truist Securities analyst Richard Newitter initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces ...

Core News & Articles

Lake Street analyst Frank Takkinen assumes Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces Price Target of $30.

 goldman-sachs-bullish-on-dexcom-and-insulet-as-diabetes-tech-surges

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neu...

Core News & Articles

Goldman Sachs analyst David Roman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Neutral rating and announces Price...

Core News & Articles

Wolfe Research analyst Mike Polark initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Outperform rating and announces P...

Core News & Articles

Beta Bionics (NASDAQ:BBNX) raises FY2025 sales outlook from $80.00 million-$85.00 million to $82.00 million-$87.00 million vs $...

Core News & Articles

Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.46...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION